Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

Key Points

• Compare the efficacy of oral temozolomide against standard dacarbazine (DTIC) in patients with advanced metastatic malignant melanoma.
• Conducted a randomized phase III clinical trial comparing oral temozolomide directly with intravenous dacarbazine.
• Enrolled patients diagnosed with advanced metastatic malignant melanoma.
• Temozolomide achieved therapeutic efficacy equal to that of standard dacarbazine.
• Oral administration of temozolomide provided a viable alternative to intravenous dacarbazine regimens.